We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...

Sanofi SNY announced that it has entered into a definitive agreement to acquire Blueprint Medicines BPMC for a total deal value of up to $9.5 billion. Following the announcement, shares of BPMC ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

Looking to further amp up its immunology business, Sanofi has agreed to acquire Blueprint Medicines in a deal that could be worth as much as $9.5 billion.

Sanofi (SNY, SAN.PA) is set to buy Blueprint Medicines (BPMC) for over $9 billion, while Bristol-Myers ... Analyst on Sanofi-Blueprint deal. Brad Smith and Madison Mills . Mon, Jun 2, 2025 ...

Investing.com -- Shares of Blueprint Medicines Corp (NASDAQ: BPMC) surged 26.5% following the announcement that the biopharmaceutical company will be acquired by Sanofi (EPA: SASY) (NASDAQ: SNY) in a ...

Sanofi SAN -1.02%decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.04%increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...

Sanofi has announced that it will be expanding its respiratory vaccines pipeline by acquiring UK-based Vicebio for up to ...

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

PARIS (Reuters) -France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a ...

In other recent news, Blueprint Medicines has reported a surprising first-quarter 2025 earnings per share of $0.01, significantly surpassing the forecasted -$0.49.

Sanofi’s offer to purchase Blueprint includes a payment of $129.00 per share in cash, which is a 27% premium over Blueprint’s closing price on May 30, 2025.